Elevation Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Elevation Wealth Partners's REGN Position: Q2 2026 in Review
Elevation Wealth Partners increased its Regeneron Pharmaceuticals (REGN) stake by 33% in Q2 2026, buying an estimated $2.72K and bringing the position to 16 shares worth $9.98K. The position accounts for ﹤0.01% of the portfolio, ranked #809.
Elevation Wealth Partners first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Elevation Wealth Partners held 16 shares of Regeneron Pharmaceuticals worth $9.98K as of Q2 2026.
- Elevation Wealth Partners bought 4 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.72K.
- Regeneron Pharmaceuticals made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #809 holding.
- Elevation Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.